The goal of this project is to develop an ultra-sensitive, point-of-care rapid diagnostic test (RDT) that detects fM concentrations of hepatitis C (HCV) core antigen. An HCV antigen test provides two major advantages over an antibody test: it detects active viral infection, and it detects the infections ~60 days earlier. The RDT will be used to identify patients with chronic hepatitis C infection and to monitor treatment response. The test is composed of 3 steps: 1) separating plasma from blood; 2) extricating antigens from virions and immune complexes; and 3) detecting antigens.
|Effective start/end date||2/10/17 → 3/31/18|
- Northwestern Global Health Foundation (Agmt 4/5/2017 // Amendment Nr. 1)
- Foundation for Innovative New Diagnostics (Agmt 4/5/2017 // Amendment Nr. 1)